CD8A and cancer: In addition, we believe that TMEM123 may be an attractive target for CD8+ based immunotherapy, for the design of molecular agonists able to promote the recruitment of T cells to the tumor site and attack of cancer cells, mediating anti-cancer Th1 immune responses.